To appraise the clinical and cost effectiveness of cabozantinib within its marketing authorisation for previously treated advanced hepatocellular carcinoma.
 
Status In progress
Decision Selected
Process STA 2018
ID number 3917

Provisional Schedule

Committee meeting: 1 02 August 2022
Expected publication 12 October 2022

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Stakeholders

Companies sponsors Ipsen (cabozantinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups British Liver Trust
Professional groups Association of Cancer Physicians
  British Association for the Study of the Liver (BASL)
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Assessment group None
Comparator companies Bayer (regorafenib) (confidentiality agreement signed, participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
22 November 2021 Invitation to participate
23 July 2021 We recently contacted all stakeholders for the appraisal of cabozantinib for previously treated advanced hepatocellular carcinoma [ID3917] regarding a delay to this topic for operational reasons. Cabozantinib for previously treated advanced hepatocellular carcinoma has now been rescheduled into the work programme and the appraisal is due to start late November 2021 and will be discussed at committee in early August 2022. The new timelines are subject to the work programme capacity and we will continue to review our plans and update our stakeholders accordingly.
07 May 2021 NICE has taken the decision to pause this appraisal due to operational reasons. The timelines are currently to be confirmed.
19 March 2021 - 13 April 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
05 February 2021 In progress. Topic in progress

For further information on our processes and methods, please see our CHTE processes and methods manual